

Oregon Prescription Drug Monitoring Program

Prescription Drug Monitoring Program Advisory Commission

Tina Kotek, Governor



Oregon Prescription Drug Monitoring Program Advisory Commission

October 17, 2025 1:00 PM Meeting Minutes

Meeting Contact: Stephanie Vesik, Stephanie.g.vesik@oha.oregon.gov, 971-200-9463

Advisory Commission Attendees:

Laura Armstrong, OD, MEd, FAAO – Chair, Optometrist, representing the Board of Optometry and Oregon Optometric Physicians Association

John Hinton, DO, MPH – Physician, representing Osteopathic Physicians and Surgeons of Oregon

Maureen McAvoy Jemison – Public member with expertise in information technology

Lina Dorfmeister CRNA NSPM-c – Pain and addiction management clinic, Coos Bay, OR

Katie Zinno – Public member and patient advocate, living with chronic diseases

Leah Hickson, DDS, PC – Dentist, representing the Oregon Dental Association

Absent:

Tracy Klein - PhD, FNP, Representing Oregon Nurses Association

Dan Kennedy – Oregon State Pharmacy Association

Kaley Bourgeois, ND – Naturopathic physician representing the Oregon Association of Naturopathic Physicians

OHA Staff Attendees:

Drew Simpson – Information Systems Manager

Stephanie Vesik – Program Coordinator

Tamara Ramirez – PDMP Operations and Coordination Specialist

Bryan Loy – Research Analyst, PDMP Data Stewardship

Ariane Erickson – Research Analyst, overseeing quarterly and annual metrics for PDMP.

Elizabeth McCarthy – Overdose Epidemiologist and PDMP Epidemiologist

Introductions

Meeting called to order by Laura Armstrong. Members and staff introduced themselves.

Notable: Leah Hickson joined representing Oregon Dental Association. John Hinton announced this was his last meeting.

Review of Previous Meeting's Minutes

Motion to approve by Leah Hickson; seconded by John Hinton. Minutes approved without changes.

Standing Agenda Items

a. Review quarterly metrics

Quarterly Report

Ariane Erickson reported to the commission on the PDMP quarterly metrics for the 3rd quarter of 2025. Enrollment steady at 89% of all providers required by state mandate to register with, 98% of top prescribers enrolled.

Ariane discussed the impact the January 2025, start of collection of Schedule V controlled substances and veterinary drugs added to PDMP.

Automated queries were 3.1% higher than the previous quarter, web queries increased by 3.4%; and integrated reports declined to baseline.

Of reported prescriptions of amphetamine (+10%) and methylphenidate (+11.2%) increased over the last quarter and pregabalin entered into the top 10 most prescribed controlled substances reported to the Oregon Prescription Drug Monitoring Program.

Gateway usage through Quarter 3 remained stable with 2,178 integrated facilities and 23,816 users.

Pharmacy Compliance

Stephanie Vesik discussed pharmacy compliance and the creation of a veterinary whitelist allowing veterinarian prescriptions for non-controlled gabapentin to be tracked. Further pharmacy compliance efforts include the removal of X-waivers from OR PDMP profiles, noting that DEA concluded the X-DEA waiver program in 2023 and all prescriptions filled under an X-DEA are indicative of a pharmacy entry error. Lastly it was noted that the continued Rite Aid Pharmacy chain closures are being monitored and transitions to new ownership tracked and updated in the OR PDMP.

b. Research study updates

Bryan Loy discussed the PDMP's involvement in research studies being conducted and shared that there are currently 4 active projects with an additional 2 in review. There was a discussion regarding a research data request from Slocum Orthopedic interested in a project on adolescent ACL surgery and opioid prescribing.

It was noted that to date there are a total of 48 PDMP-related publications utilizing OR PDMP data.

c. Subcommittee Activities Update

Liz McCarthy discussed the OR PDMP Subcommittee's latest activities highlighting that a meeting occurred on Oct 20; while that meeting did not have a quorum they did have a discussion on the inclusion of Schedule V codeine in measures.

The subcommittee also discussed and expressed interest in lowering high opioid MME threshold from 200 to 150.

d. Legislative Update

Drew Simpson reported the previous legislation on tribal data sharing is progressing. In 2026, it will be a short session and it currently appears to be a low likelihood of PDMP bills during this session. Drew also discussed that in future sessions there would likely be efforts towards further interstate data sharing and PDMP user fees and the need for an increase to ensure program sustainability.

Old Business

Bryan Loy presented findings from a report of stimulant prescriptions within the OR PDMP. Highlights of this report included:

- Stimulant prescribing has tripled since 2012;
- 4.4% of population received stimulants in Q2 2025;
- Highest death rates were noted to have stimulant and benzodiazepine co-prescribing.
- Modafinil was linked to higher hospitalization and death rates.
- Limitations: the study was descriptive only, not causal.

New Business

Drew Simpson noted a few items for the interest of the Advisory Commission. He discussed the ongoing RFP (Request for Proposal) for an updated PDMP vendor contract has been delayed, currently Oregon is engaging in a special procurement with Bamboo Health to provide additional time.

Further that the PDMP did submit an application for a Harold Rogers Grant (\$2M) and the program has not heard

PDMP staff discussed with the commission the empty public seat that they are pursuing to be filled and ongoing challenge filling the OMA seat challenges that have been going on the last 2 years.

Open Issues

No Open issues were addressed during the meeting.

Public Comment

There were no members of the public in attendance.

Next Meeting Date: January 16, 2026